Spark Therapeutics

#70–David Sinclair, PhD: How cellular reprogramming could slow our aging clock, & the latest on NAD

Peter Attia MD

A company with an FDA-approved drug that uses gene therapy to treat a type of retinal degeneration, with treatments costing hundreds of thousands of dollars.